 Peter Mourani
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 23 | 2021 | 331 | 5.040 |
Why?
| | Intensive Care Units, Pediatric | 26 | 2023 | 147 | 2.890 |
Why?
| | Cardiopulmonary Resuscitation | 14 | 2023 | 220 | 2.410 |
Why?
| | Heart Arrest | 15 | 2023 | 289 | 2.370 |
Why?
| | Respiration, Artificial | 17 | 2023 | 526 | 2.160 |
Why?
| | Critical Illness | 23 | 2024 | 643 | 2.090 |
Why?
| | Hypertension, Pulmonary | 13 | 2023 | 1737 | 2.050 |
Why?
| | Infant, Premature | 17 | 2021 | 478 | 2.040 |
Why?
| | Pneumonia, Ventilator-Associated | 3 | 2021 | 40 | 1.930 |
Why?
| | Microbiota | 8 | 2024 | 649 | 1.860 |
Why?
| | Shock, Septic | 11 | 2023 | 185 | 1.810 |
Why?
| | Sepsis | 12 | 2023 | 508 | 1.490 |
Why?
| | Child | 86 | 2024 | 18362 | 1.370 |
Why?
| | Respiratory Insufficiency | 5 | 2021 | 291 | 1.350 |
Why?
| | Trachea | 3 | 2017 | 235 | 1.350 |
Why?
| | Prospective Studies | 42 | 2024 | 6218 | 1.340 |
Why?
| | Infant, Newborn | 40 | 2024 | 5035 | 1.310 |
Why?
| | Respiratory Tract Infections | 5 | 2024 | 321 | 1.300 |
Why?
| | Vascular Diseases | 5 | 2020 | 230 | 1.120 |
Why?
| | Critical Care | 6 | 2021 | 474 | 1.060 |
Why?
| | Premature Birth | 4 | 2021 | 276 | 1.030 |
Why?
| | Infant | 42 | 2024 | 7936 | 0.970 |
Why?
| | Echocardiography | 7 | 2021 | 555 | 0.930 |
Why?
| | Lung | 9 | 2024 | 3593 | 0.920 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2022 | 218 | 0.900 |
Why?
| | Humans | 125 | 2024 | 114925 | 0.880 |
Why?
| | Influenza, Human | 9 | 2023 | 546 | 0.880 |
Why?
| | Child, Preschool | 35 | 2024 | 9083 | 0.880 |
Why?
| | Heart Ventricles | 2 | 2021 | 711 | 0.870 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 32 | 0.870 |
Why?
| | Intensive Care Units | 9 | 2023 | 619 | 0.840 |
Why?
| | RNA, Ribosomal, 16S | 4 | 2021 | 486 | 0.800 |
Why?
| | Ventricular Function, Right | 2 | 2021 | 252 | 0.780 |
Why?
| | Intubation, Intratracheal | 3 | 2019 | 215 | 0.770 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 98 | 0.770 |
Why?
| | Quality of Life | 12 | 2024 | 2359 | 0.730 |
Why?
| | Tobacco Smoke Pollution | 1 | 2023 | 217 | 0.700 |
Why?
| | Patient Discharge | 11 | 2024 | 768 | 0.670 |
Why?
| | Aftercare | 5 | 2024 | 187 | 0.640 |
Why?
| | Male | 55 | 2024 | 55655 | 0.600 |
Why?
| | Nutritional Support | 1 | 2017 | 27 | 0.600 |
Why?
| | Respiratory Tract Diseases | 1 | 2019 | 140 | 0.590 |
Why?
| | Echocardiography, Doppler | 3 | 2018 | 93 | 0.590 |
Why?
| | Female | 58 | 2024 | 59571 | 0.580 |
Why?
| | Gestational Age | 7 | 2021 | 759 | 0.580 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.570 |
Why?
| | Respiratory Syncytial Viruses | 2 | 2013 | 46 | 0.540 |
Why?
| | Risk Factors | 20 | 2022 | 8637 | 0.530 |
Why?
| | Coinfection | 3 | 2022 | 120 | 0.530 |
Why?
| | Echocardiography, Doppler, Pulsed | 1 | 2015 | 9 | 0.510 |
Why?
| | Adolescent | 34 | 2023 | 17826 | 0.500 |
Why?
| | Energy Intake | 1 | 2017 | 419 | 0.490 |
Why?
| | Nitric Oxide | 6 | 2022 | 827 | 0.480 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2014 | 15 | 0.460 |
Why?
| | Chlorides | 3 | 2020 | 127 | 0.460 |
Why?
| | Retrospective Studies | 26 | 2023 | 12543 | 0.460 |
Why?
| | Paramyxoviridae Infections | 1 | 2013 | 10 | 0.460 |
Why?
| | Metapneumovirus | 1 | 2013 | 12 | 0.450 |
Why?
| | Myocardial Contraction | 1 | 2015 | 312 | 0.450 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 96 | 0.440 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2015 | 129 | 0.440 |
Why?
| | Bacteria | 4 | 2022 | 728 | 0.430 |
Why?
| | Brain Injuries, Traumatic | 3 | 2023 | 300 | 0.420 |
Why?
| | Energy Metabolism | 1 | 2017 | 724 | 0.420 |
Why?
| | Patient Readmission | 2 | 2018 | 608 | 0.420 |
Why?
| | Pulmonary Embolism | 2 | 2012 | 183 | 0.410 |
Why?
| | Lung Diseases | 2 | 2010 | 703 | 0.410 |
Why?
| | Peripheral Vascular Diseases | 1 | 2013 | 98 | 0.410 |
Why?
| | Oxygen | 3 | 2019 | 853 | 0.410 |
Why?
| | Bacterial Infections | 3 | 2023 | 219 | 0.400 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 468 | 0.400 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 231 | 0.390 |
Why?
| | Denys-Drash Syndrome | 1 | 2011 | 4 | 0.390 |
Why?
| | Embolectomy | 1 | 2011 | 11 | 0.380 |
Why?
| | Bereavement | 2 | 2021 | 49 | 0.370 |
Why?
| | Acute Kidney Injury | 4 | 2021 | 638 | 0.370 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 360 | 0.370 |
Why?
| | Influenza A virus | 3 | 2020 | 90 | 0.370 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1028 | 0.350 |
Why?
| | Wilms Tumor | 1 | 2011 | 69 | 0.350 |
Why?
| | Milrinone | 2 | 2021 | 24 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1400 | 0.350 |
Why?
| | Vasodilator Agents | 3 | 2021 | 305 | 0.350 |
Why?
| | Water-Electrolyte Imbalance | 2 | 2020 | 26 | 0.320 |
Why?
| | Coronary Care Units | 2 | 2018 | 13 | 0.310 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 191 | 0.310 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2008 | 82 | 0.310 |
Why?
| | Infant, Extremely Premature | 2 | 2020 | 57 | 0.310 |
Why?
| | Sulfones | 1 | 2008 | 97 | 0.300 |
Why?
| | Multiple Organ Failure | 3 | 2023 | 142 | 0.300 |
Why?
| | Logistic Models | 6 | 2019 | 1843 | 0.300 |
Why?
| | Hernia, Diaphragmatic | 1 | 2008 | 66 | 0.300 |
Why?
| | Quality Improvement | 3 | 2022 | 954 | 0.290 |
Why?
| | Cohort Studies | 13 | 2022 | 4903 | 0.290 |
Why?
| | Heart Diseases | 2 | 2023 | 330 | 0.290 |
Why?
| | Administration, Inhalation | 5 | 2022 | 642 | 0.290 |
Why?
| | Health Resources | 4 | 2022 | 122 | 0.290 |
Why?
| | Kidney Neoplasms | 1 | 2011 | 334 | 0.280 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 240 | 0.280 |
Why?
| | Research Design | 4 | 2022 | 932 | 0.280 |
Why?
| | Staphylococcus | 2 | 2017 | 69 | 0.280 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 336 | 0.280 |
Why?
| | Metagenomics | 4 | 2023 | 131 | 0.270 |
Why?
| | Piperazines | 1 | 2008 | 313 | 0.270 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4427 | 0.270 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2008 | 186 | 0.260 |
Why?
| | Hospital Mortality | 8 | 2023 | 776 | 0.260 |
Why?
| | Length of Stay | 4 | 2020 | 949 | 0.260 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 1477 | 0.250 |
Why?
| | Biomarkers | 8 | 2023 | 3418 | 0.250 |
Why?
| | Pregnancy | 9 | 2022 | 5525 | 0.240 |
Why?
| | Time Factors | 9 | 2020 | 6125 | 0.240 |
Why?
| | Diastole | 3 | 2019 | 131 | 0.240 |
Why?
| | Ribosomal Protein S6 | 1 | 2004 | 15 | 0.230 |
Why?
| | DEAD Box Protein 58 | 2 | 2022 | 8 | 0.230 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 37 | 0.230 |
Why?
| | Longitudinal Studies | 4 | 2020 | 2382 | 0.230 |
Why?
| | Tunica Intima | 1 | 2004 | 78 | 0.230 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2004 | 417 | 0.230 |
Why?
| | Skin Pigmentation | 1 | 2024 | 39 | 0.220 |
Why?
| | Oximetry | 1 | 2024 | 81 | 0.220 |
Why?
| | Epinephrine | 2 | 2022 | 167 | 0.220 |
Why?
| | Respiration | 1 | 2024 | 180 | 0.210 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.210 |
Why?
| | Age Factors | 6 | 2021 | 2891 | 0.210 |
Why?
| | Treatment Outcome | 11 | 2022 | 9105 | 0.210 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2022 | 13 | 0.210 |
Why?
| | Receptors, Immunologic | 2 | 2022 | 201 | 0.210 |
Why?
| | Cotinine | 1 | 2023 | 67 | 0.210 |
Why?
| | Wounds and Injuries | 2 | 2021 | 723 | 0.210 |
Why?
| | Hypotension | 1 | 2023 | 113 | 0.200 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2022 | 11 | 0.200 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2004 | 236 | 0.200 |
Why?
| | Sodium | 1 | 2022 | 182 | 0.200 |
Why?
| | Protein Kinases | 1 | 2004 | 307 | 0.200 |
Why?
| | Glasgow Coma Scale | 4 | 2023 | 144 | 0.200 |
Why?
| | Central Venous Catheters | 1 | 2022 | 39 | 0.200 |
Why?
| | Smoke | 1 | 2023 | 127 | 0.190 |
Why?
| | Parents | 4 | 2021 | 1191 | 0.190 |
Why?
| | United States | 11 | 2022 | 12209 | 0.190 |
Why?
| | Central Venous Pressure | 1 | 2021 | 12 | 0.190 |
Why?
| | Prone Position | 1 | 2021 | 27 | 0.190 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2022 | 61 | 0.190 |
Why?
| | Capnography | 1 | 2021 | 11 | 0.190 |
Why?
| | Shock | 1 | 2022 | 75 | 0.190 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1081 | 0.190 |
Why?
| | Patient Positioning | 1 | 2021 | 42 | 0.190 |
Why?
| | Catheterization, Central Venous | 1 | 2022 | 81 | 0.190 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2022 | 122 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2022 | 82 | 0.180 |
Why?
| | Common Data Elements | 1 | 2020 | 10 | 0.180 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2021 | 47 | 0.180 |
Why?
| | Thoracic Injuries | 1 | 2021 | 53 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2020 | 15 | 0.180 |
Why?
| | Communicable Diseases | 1 | 2022 | 130 | 0.180 |
Why?
| | Iloprost | 1 | 2021 | 46 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3053 | 0.180 |
Why?
| | Spinal Injuries | 1 | 2021 | 48 | 0.180 |
Why?
| | Multiple Trauma | 1 | 2021 | 89 | 0.180 |
Why?
| | Young Adult | 9 | 2022 | 10476 | 0.180 |
Why?
| | Vasopressins | 1 | 2021 | 56 | 0.180 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2021 | 316 | 0.180 |
Why?
| | Extremities | 1 | 2021 | 113 | 0.180 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 71 | 0.180 |
Why?
| | Abdominal Injuries | 1 | 2021 | 95 | 0.180 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 611 | 0.180 |
Why?
| | Epoprostenol | 1 | 2021 | 133 | 0.180 |
Why?
| | Angiogenic Proteins | 1 | 2020 | 18 | 0.170 |
Why?
| | Radiography, Thoracic | 1 | 2021 | 162 | 0.170 |
Why?
| | Morbidity | 4 | 2022 | 277 | 0.170 |
Why?
| | Caregivers | 3 | 2021 | 712 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2018 | 1440 | 0.170 |
Why?
| | Medical Audit | 1 | 2020 | 75 | 0.170 |
Why?
| | Mannose-Binding Lectin | 1 | 2019 | 21 | 0.170 |
Why?
| | Medical Records | 1 | 2020 | 154 | 0.160 |
Why?
| | Nervous System Diseases | 1 | 2022 | 252 | 0.160 |
Why?
| | Medicine | 1 | 2020 | 102 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2023 | 414 | 0.160 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2020 | 80 | 0.160 |
Why?
| | Reproducibility of Results | 4 | 2020 | 2769 | 0.160 |
Why?
| | Pulmonary Circulation | 2 | 2015 | 408 | 0.160 |
Why?
| | CRISPR-Cas Systems | 1 | 2019 | 78 | 0.160 |
Why?
| | Adult | 10 | 2024 | 30604 | 0.160 |
Why?
| | Cardiotonic Agents | 1 | 2019 | 119 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 126 | 0.160 |
Why?
| | Drug Resistance, Bacterial | 1 | 2019 | 155 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2102 | 0.160 |
Why?
| | Blood Pressure | 4 | 2023 | 1537 | 0.150 |
Why?
| | Hospitalization | 4 | 2023 | 1754 | 0.150 |
Why?
| | Diabetes, Gestational | 1 | 2022 | 281 | 0.150 |
Why?
| | Proteomics | 3 | 2020 | 844 | 0.150 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 25 | 0.150 |
Why?
| | Academic Medical Centers | 2 | 2017 | 415 | 0.150 |
Why?
| | Calorimetry, Indirect | 1 | 2017 | 69 | 0.150 |
Why?
| | Renal Replacement Therapy | 1 | 2018 | 66 | 0.150 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.150 |
Why?
| | Chorioamnionitis | 1 | 2017 | 36 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2018 | 75 | 0.140 |
Why?
| | Motivation | 1 | 2021 | 495 | 0.140 |
Why?
| | Respiratory System | 1 | 2018 | 138 | 0.140 |
Why?
| | Toll-Like Receptor 4 | 1 | 2020 | 286 | 0.140 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2017 | 66 | 0.140 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 176 | 0.140 |
Why?
| | Mutation, Missense | 1 | 2019 | 295 | 0.140 |
Why?
| | Heart Failure | 2 | 2021 | 1952 | 0.140 |
Why?
| | Inservice Training | 1 | 2018 | 107 | 0.140 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 474 | 0.140 |
Why?
| | Delirium | 1 | 2018 | 66 | 0.140 |
Why?
| | Dysbiosis | 1 | 2018 | 146 | 0.140 |
Why?
| | Chronic Disease | 3 | 2022 | 1593 | 0.140 |
Why?
| | Pneumonia | 1 | 2022 | 568 | 0.140 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 176 | 0.140 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 441 | 0.130 |
Why?
| | Hemodynamics | 3 | 2023 | 1014 | 0.130 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 413 | 0.130 |
Why?
| | MicroRNAs | 1 | 2022 | 601 | 0.130 |
Why?
| | Infant, Low Birth Weight | 2 | 2015 | 125 | 0.130 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2017 | 102 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 297 | 0.130 |
Why?
| | Fibroblasts | 1 | 2020 | 839 | 0.130 |
Why?
| | Mothers | 2 | 2022 | 651 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2020 | 2542 | 0.130 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 18 | 0.130 |
Why?
| | Needs Assessment | 1 | 2017 | 315 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2019 | 292 | 0.130 |
Why?
| | Delphi Technique | 3 | 2020 | 162 | 0.130 |
Why?
| | Pre-Eclampsia | 1 | 2017 | 165 | 0.130 |
Why?
| | Computational Biology | 1 | 2019 | 531 | 0.130 |
Why?
| | Organ Dysfunction Scores | 3 | 2020 | 39 | 0.130 |
Why?
| | Indiana | 1 | 2015 | 27 | 0.120 |
Why?
| | Medical Informatics | 1 | 2016 | 92 | 0.120 |
Why?
| | Hypokalemia | 1 | 2014 | 25 | 0.120 |
Why?
| | Trauma Centers | 3 | 2022 | 325 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2019 | 342 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 344 | 0.120 |
Why?
| | Hypertension | 2 | 2019 | 1059 | 0.110 |
Why?
| | Bronchiolitis, Viral | 1 | 2013 | 10 | 0.110 |
Why?
| | Metabolomics | 1 | 2018 | 527 | 0.110 |
Why?
| | Hospitals, Pediatric | 3 | 2023 | 479 | 0.110 |
Why?
| | Birth Weight | 1 | 2017 | 440 | 0.110 |
Why?
| | Schools, Medical | 1 | 2015 | 122 | 0.110 |
Why?
| | Signal Transduction | 2 | 2020 | 4524 | 0.110 |
Why?
| | Smoking | 2 | 2018 | 1391 | 0.110 |
Why?
| | Patient Care Team | 1 | 2018 | 516 | 0.110 |
Why?
| | Risk Assessment | 5 | 2018 | 2975 | 0.110 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 756 | 0.110 |
Why?
| | Colorado | 4 | 2017 | 4089 | 0.110 |
Why?
| | Physicians | 1 | 2021 | 772 | 0.110 |
Why?
| | Nasopharynx | 2 | 2023 | 63 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 42 | 0.100 |
Why?
| | Prognosis | 4 | 2023 | 3344 | 0.100 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 160 | 0.100 |
Why?
| | Incidence | 2 | 2018 | 2316 | 0.100 |
Why?
| | Precision Medicine | 1 | 2016 | 339 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2012 | 81 | 0.100 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 665 | 0.100 |
Why?
| | Risk | 2 | 2012 | 815 | 0.100 |
Why?
| | Carbon Dioxide | 2 | 2023 | 218 | 0.100 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 26 | 0.100 |
Why?
| | Polysaccharides | 1 | 2012 | 78 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2017 | 450 | 0.100 |
Why?
| | Abbreviated Injury Scale | 2 | 2021 | 21 | 0.100 |
Why?
| | Enoxaparin | 1 | 2012 | 52 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1008 | 0.100 |
Why?
| | Suction | 1 | 2011 | 31 | 0.100 |
Why?
| | Bacterial Load | 1 | 2011 | 58 | 0.100 |
Why?
| | Immunomodulation | 1 | 2012 | 84 | 0.100 |
Why?
| | Grief | 2 | 2021 | 35 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2012 | 285 | 0.100 |
Why?
| | Ultrasonography | 1 | 2015 | 633 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2017 | 1022 | 0.090 |
Why?
| | Anticoagulants | 2 | 2012 | 547 | 0.090 |
Why?
| | Pressure | 2 | 2023 | 218 | 0.090 |
Why?
| | RNA, Ribosomal | 1 | 2011 | 157 | 0.090 |
Why?
| | Aged | 3 | 2024 | 19120 | 0.090 |
Why?
| | Interferons | 2 | 2022 | 150 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 225 | 0.090 |
Why?
| | Metagenome | 1 | 2011 | 122 | 0.090 |
Why?
| | RNA, Bacterial | 1 | 2011 | 174 | 0.090 |
Why?
| | Survival Rate | 3 | 2019 | 1644 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 192 | 0.090 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 233 | 0.090 |
Why?
| | Fetal Blood | 1 | 2012 | 270 | 0.090 |
Why?
| | Vitamin D | 1 | 2013 | 341 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2326 | 0.090 |
Why?
| | Blood Glucose | 2 | 2019 | 1821 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1700 | 0.090 |
Why?
| | Intensive Care, Neonatal | 1 | 2010 | 39 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2013 | 429 | 0.080 |
Why?
| | Stakeholder Participation | 2 | 2020 | 73 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 718 | 0.080 |
Why?
| | Influenza Vaccines | 1 | 2014 | 497 | 0.080 |
Why?
| | Survivors | 2 | 2022 | 411 | 0.080 |
Why?
| | Potassium | 2 | 2022 | 128 | 0.080 |
Why?
| | Sildenafil Citrate | 1 | 2008 | 57 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2021 | 4634 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 2132 | 0.080 |
Why?
| | Pediatrics | 1 | 2016 | 984 | 0.080 |
Why?
| | Hypoxia | 2 | 2024 | 960 | 0.070 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2008 | 63 | 0.070 |
Why?
| | Stem Cells | 1 | 2012 | 546 | 0.070 |
Why?
| | Stroke Volume | 2 | 2021 | 510 | 0.070 |
Why?
| | Purines | 1 | 2008 | 159 | 0.070 |
Why?
| | Transcriptome | 2 | 2023 | 728 | 0.070 |
Why?
| | Pulmonary Edema | 1 | 2008 | 116 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 929 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1220 | 0.070 |
Why?
| | Diseases in Twins | 1 | 2008 | 174 | 0.070 |
Why?
| | Gene Expression | 2 | 2022 | 1422 | 0.070 |
Why?
| | Clinical Competence | 2 | 2023 | 901 | 0.070 |
Why?
| | Phenotype | 2 | 2023 | 2817 | 0.060 |
Why?
| | Neovascularization, Physiologic | 2 | 2012 | 173 | 0.060 |
Why?
| | Cell Division | 2 | 2004 | 759 | 0.060 |
Why?
| | Cytokines | 1 | 2012 | 1843 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1019 | 0.060 |
Why?
| | Culture Media, Serum-Free | 1 | 2004 | 42 | 0.060 |
Why?
| | Chromones | 1 | 2004 | 35 | 0.060 |
Why?
| | Diffuse Axonal Injury | 1 | 2023 | 5 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2008 | 535 | 0.060 |
Why?
| | Carotid Artery Injuries | 1 | 2004 | 43 | 0.060 |
Why?
| | Aorta | 2 | 2004 | 390 | 0.060 |
Why?
| | Drug Resistance, Microbial | 1 | 2024 | 67 | 0.060 |
Why?
| | Disaccharides | 1 | 2023 | 16 | 0.060 |
Why?
| | Syndecan-1 | 1 | 2023 | 27 | 0.060 |
Why?
| | Androstadienes | 1 | 2004 | 97 | 0.060 |
Why?
| | Oligonucleotides, Antisense | 1 | 2004 | 100 | 0.060 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2023 | 19 | 0.060 |
Why?
| | Corpus Callosum | 1 | 2023 | 56 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2023 | 39 | 0.060 |
Why?
| | Glycocalyx | 1 | 2023 | 18 | 0.060 |
Why?
| | Water-Electrolyte Balance | 1 | 2023 | 26 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 33 | 0.050 |
Why?
| | Morpholines | 1 | 2004 | 102 | 0.050 |
Why?
| | Probability | 1 | 2004 | 291 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 160 | 0.050 |
Why?
| | Hyperoxia | 1 | 2004 | 100 | 0.050 |
Why?
| | Proteoglycans | 1 | 2023 | 107 | 0.050 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 140 | 0.050 |
Why?
| | Vascular Resistance | 1 | 2004 | 338 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2022 | 1893 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 140 | 0.050 |
Why?
| | Methicillin | 1 | 2022 | 11 | 0.050 |
Why?
| | Sirolimus | 1 | 2004 | 181 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2022 | 48 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 524 | 0.050 |
Why?
| | White Matter | 1 | 2023 | 102 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2022 | 40 | 0.050 |
Why?
| | RNA, Viral | 2 | 2017 | 565 | 0.050 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 254 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 48 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 330 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 400 | 0.050 |
Why?
| | Protein Processing, Post-Translational | 1 | 2004 | 399 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2004 | 2211 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 207 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1729 | 0.050 |
Why?
| | Neonatologists | 1 | 2021 | 3 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2004 | 359 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 390 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 157 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 42 | 0.050 |
Why?
| | Influenza in Birds | 1 | 2020 | 3 | 0.050 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 76 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2004 | 752 | 0.050 |
Why?
| | Stromal Cells | 1 | 2020 | 96 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2020 | 73 | 0.040 |
Why?
| | Birds | 1 | 2020 | 77 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 41 | 0.040 |
Why?
| | Hematoma, Subdural | 1 | 2019 | 16 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 937 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2021 | 310 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2020 | 69 | 0.040 |
Why?
| | Phosphorylation | 1 | 2004 | 1572 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 235 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 457 | 0.040 |
Why?
| | Skull Fractures | 1 | 2019 | 29 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 40 | 0.040 |
Why?
| | Child Health | 1 | 2020 | 126 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2022 | 723 | 0.040 |
Why?
| | Cardiac Output | 1 | 2019 | 143 | 0.040 |
Why?
| | Intracranial Hemorrhages | 1 | 2019 | 76 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 385 | 0.040 |
Why?
| | Maternal Exposure | 2 | 2012 | 138 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 189 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 104 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.040 |
Why?
| | Complement Activation | 1 | 2021 | 340 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3008 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 499 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 187 | 0.040 |
Why?
| | American Heart Association | 1 | 2020 | 264 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 947 | 0.040 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 141 | 0.040 |
Why?
| | Animals | 5 | 2020 | 31837 | 0.040 |
Why?
| | Rats | 2 | 2004 | 4963 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2024 | 480 | 0.040 |
Why?
| | Amino Acid Substitution | 1 | 2019 | 262 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2021 | 239 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 448 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 534 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 331 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2004 | 796 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 244 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1372 | 0.040 |
Why?
| | Mortality | 1 | 2020 | 288 | 0.040 |
Why?
| | Data Collection | 1 | 2020 | 623 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 424 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1523 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2017 | 69 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 250 | 0.040 |
Why?
| | Causality | 1 | 2017 | 105 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2020 | 436 | 0.040 |
Why?
| | Calcium | 1 | 2022 | 1104 | 0.030 |
Why?
| | Homozygote | 1 | 2017 | 188 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1355 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 737 | 0.030 |
Why?
| | Family | 1 | 2020 | 590 | 0.030 |
Why?
| | Point-of-Care Systems | 1 | 2018 | 139 | 0.030 |
Why?
| | Social Class | 1 | 2018 | 204 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2004 | 3897 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1760 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 338 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2020 | 547 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 106 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 770 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 534 | 0.030 |
Why?
| | Communication | 1 | 2021 | 747 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1458 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2022 | 2558 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1134 | 0.030 |
Why?
| | Proteins | 1 | 2000 | 912 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 868 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 647 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1325 | 0.030 |
Why?
| | Orthomyxoviridae | 1 | 2014 | 35 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1801 | 0.030 |
Why?
| | Child Health Services | 1 | 2016 | 177 | 0.030 |
Why?
| | Protein Binding | 1 | 2019 | 1897 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1125 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1133 | 0.030 |
Why?
| | Inflammation | 1 | 2023 | 2485 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1215 | 0.030 |
Why?
| | Immune System | 1 | 2013 | 173 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1474 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1630 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 158 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 290 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2013 | 458 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 562 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2012 | 496 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2392 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1087 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2012 | 685 | 0.020 |
Why?
| | Global Health | 1 | 2008 | 288 | 0.020 |
Why?
| | Mice | 1 | 2020 | 14935 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 26801 | 0.010 |
Why?
| | Embryo, Mammalian | 1 | 2000 | 214 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2000 | 524 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3248 | 0.010 |
Why?
|
|
Mourani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|